WDTN

Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board

Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD) CAB and Oryzon establish primary and ...
Psychology Today

Speaking Out for Men with BPD

Thirty years ago when I first started training as a psychiatrist and providing inpatient care to adolescents and young adults with borderline personality disorder (BPD), there was a tremendous amount ...
Healthline

Borderline Personality Disorder: Diagnosis and Treatment Criteria

BPD causes symptoms like emotional and relationship instability as well as higher anxiety levels. Insurance coverage for treatment may vary, requiring you to check your specific plan. Borderline ...
Morningstar

ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

Agitation-Aggression in Borderline Personality Disorder (BPD) acknowledged as a possible therapeutic indication Oryzon may use STAXI-2 Trait anger as a primary efficacy endpoint for PORTICO-2 ...